Source : WAM
The Emirates Drug Establishment (EDE) showcased its AI-driven drug efficacy design project, InSilico Medicine, during its participation at the World Health Expo (WHX 2026).
InSilico Medicine is designed to harness advanced digital models to accelerate pharmaceutical research and development, reduce costs, and improve the accuracy of compound evaluation before production.
On the sidelines of the exhibition, EDE signed a Memorandum of Understanding (MoU) with InSilico Medicine AI Limited to enhance collaboration in this area and support the development of advanced national capabilities in applying artificial intelligence to innovative medical product design.
The MoU was signed by Dr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment, and Dr. Alex Aliper, President of InSilico Medicine AI Limited.
Both parties emphasized that the partnership reflects their shared commitment to building a resilient and sustainable healthcare ecosystem, strengthening pharmaceutical security, and positioning the UAE as a leading regional hub for pharmaceutical and health technology innovation.
During the exhibition, EDE highlighted the InSilico Medicine project as a key initiative for accelerating digital transformation in drug development.
The project uses generative artificial intelligence and deep learning technologies to assess drug efficacy before production, reducing R&D costs and shortening the time required for innovative therapies to reach patients.
It also supports national priorities related to pharmaceutical security and ensures the sustainable availability of high-quality medical products at competitive prices.
Dr. Shaikha Al Mazrouei, Director of the Reference National Laboratory Drug Department at EDE, explained that the collaboration with InSilico Medicine AI Limited will enable deployment of advanced AI-driven design platforms. These platforms, based on generative models and reinforcement learning algorithms, analyse biological, chemical, and clinical data.
The technologies allow for more precise testing, generation of optimised drug compounds with improved efficacy and safety profiles, and predictive toxicity studies, while reducing reliance on animal models during early development stages.
This initiative aligns with the Emirates Drug Establishment’s commitment to advancing pharmaceutical innovation, localising biotechnology industries, upgrading the national pharmaceutical framework, and ensuring the sustainability of medical products.
It further reinforces national pharmaceutical manufacturing capabilities, enhances competitiveness, and encourages specialised research and product development within the UAE.
